<DOC>
	<DOCNO>NCT01808833</DOCNO>
	<brief_summary>The investigator hypothesize frailty assessment prior concurrent chemotherapy radiation therapy elderly predict treatment-related toxicity morbidity assessment serial time point help improve treatment outcome patient .</brief_summary>
	<brief_title>Frailty Study Older Adults Getting Chemotherapy Radiation Therapy</brief_title>
	<detailed_description />
	<criteria>Patients must one follow histologically cytologically confirm cancer : lung cancer , head neck cancer , gastric cancer , anal cancer , rectal cancer , cervix cancer , bladder cancer , must appropriate indication use standard concurrent chemotherapy plus radiation therapy define NCCN ( National Comprehensive Cancer Network ) Guidelines specific organsites . Age &gt; 70 year . ECOG ( Easter Cooperative Oncology Group ) performance status 0 , 1 2 . Life expectancy Tables show upper , middle , low quartile life expectancy woman men age 70 older use life expectancy estimate sufficient justify use concurrent chemotherapy plus radiation organ site indication . Ability understand willingness sign write informed consent document . Patients chemotherapy radiotherapy within 4 week prior enter study recover baseline adverse event due agent administer 4 week earlier . Patients receive investigational agent . Patients know distant site metastasis ( M1 disease ) brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Patients history one concurrent cancer besides cancer concurrent chemotherapy plus radiation therapy consider ineligible cancer cancer consider treatment actively treat . Patients carry preexist diagnosis HIV/AIDS combination antiretroviral therapy ineligible potential pharmacokinetic interaction chemotherapy . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate . Patients standard contraindication chemotherapy radiation therapy ineligible . Transplant recipient patient immunesuppressant agent ineligible due increase risk infection .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Frailty</keyword>
	<keyword>Geriatric oncology</keyword>
</DOC>